Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia

&NA; Several lines of evidence imply alterations in adenosine signaling in Parkinson's disease (PD). Here, we investigated cerebral changes in adenosine 2A receptor (A2AR) availability in 6‐hydroxydopamine (6‐OHDA)‐lesioned rats with and without levodopa‐induced dyskinesia (LID) using positron‐emission tomography (PET) with [11C]preladenant. In parallel dopamine type 2 receptor (D2R) imaging with [11C]raclopride PET and behavioral tests for motor and cognitive function were performed. Methods: Parametric A2AR and D2R binding potential (BPND) images were reconstructed using reference tissue models with midbrain and cerebellum as reference tissue, respectively. All images were anatomically standardized to Paxinos space and analyzed using volume‐of‐interest (VOI) and voxel‐based approaches. The behavioral alternations were assessed with the open field test, Y‐maze, novel object recognition test, cylinder test, and abnormal involuntary movement (AIM) score. In total, 28 female Wistar rats were included. Results: On the behavioral level, 6‐OHDA‐lesioned rats showed asymmetry in forepaw use and deficits in spatial memory and explorative behavior as compared to the sham‐operated animals. 15‐Days of levodopa (L‐DOPA) treatment induced dyskinesia but did not alleviate motor deficits in PD rats. Intranigral 6‐OHDA injection significantly increased D2R binding in the lesioned striatum (BPND: 2.69 ± 0.40 6‐OHDA vs. 2.31 ± 0.18 sham, + 16.6%; p = 0.03), whereas L‐DOPA treatment did not affect the D2R binding in the ipsilateral striatum of the PD rats. In addition, intranigral 6‐OHDA injection tended to decrease the A2AR availability in the lesioned striatum. The decrease became significant when data were normalized to the non‐affected side (BPND: 4.32 ± 0.41 6‐OHDA vs. 4.58 ± 0.89 sham; NS, ratio: 0.94 ± 0.03 6‐OHDA vs. 1.00 ± 0.02 sham; − 6.1%; p = 0.01). L‐DOPA treatment significantly increased A2AR binding in the affected striatum (BPND: 6.02 ± 0.91 L‐DOPA vs. 4.90 ± 0.76 saline; + 23.4%; p = 0.02). In PD rats with LID, positive correlations were found between D2R and A2AR BPND values in the ipsilateral striatum (r = 0.88, ppeak = 8.56.10−4 uncorr), and between AIM score and the D2R BPND in the contralateral striatum (r = 0.98; ppeak = 9.55.10−5 uncorr). Conclusion: A2AR availability changed in drug‐naïve and in L‐DOPA‐treated PD rats. The observed correlations of striatal D2R availability with A2AR availability and with AIM score may provide new knowledge on striatal physiology and new possibilities to further unravel the functions of these targets in the pathophysiology of PD. HighlightsL‐DOPA treatment increased A2AR availability in striatum in 6‐OHDA‐lesioned PD rats.Striatal A2AR positively correlated with D2R availability in L‐DOPA‐treated PD rats.D2R availability in the non‐lesioned striatum positively correlated with AIM scores.

[1]  B. Fredholm,et al.  Autoradiographic evidence for G-protein coupled A2-receptors in rat neostriatum using [3H]-CGS 21680 as a ligand , 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  H. Müller-Gärtner,et al.  Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  S. Kitamura,et al.  Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients , 2011, PloS one.

[4]  P. Scheltens,et al.  Test–retest variability of [11C]PIB studies in healthy subjects and AD patients , 2006, NeuroImage.

[5]  K. Fuxe,et al.  Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. , 2004, Analytical chemistry.

[6]  Johan Nuyts,et al.  Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  J. Brotchie.  Nondopaminergic mechanisms in levodopa‐induced dyskinesia , 2005, Movement disorders : official journal of the Movement Disorder Society.

[8]  K. Fuxe,et al.  Adenosine receptor–dopamine receptor interactions in the basal ganglia and their relevance for brain function , 2007, Physiology & Behavior.

[9]  M. Baba,et al.  Upregulation of striatal adenosine A2A receptor mRNA in 6‐hydroxydopamine‐lesioned rats intermittently treated with L‐DOPA , 2004, Synapse.

[10]  Edward B. Greene.  Construction and evaluation of test items. , 1941 .

[11]  J. Brotchie,et al.  Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials , 2013, Movement disorders : official journal of the Movement Disorder Society.

[12]  Michele Zoli,et al.  Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2Receptors* , 2002, The Journal of Biological Chemistry.

[13]  E. Bézard,et al.  A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey , 1997, Brain Research.

[14]  Gudmund J. W. Smith,et al.  Longitudinal follow-up of preterm children: the mother-and child relationship at 9 and 19 years of age , 2002 .

[15]  K. Leenders,et al.  Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride , 1997, Movement disorders : official journal of the Movement Disorder Society.

[16]  C. Marsden,et al.  Chronic pharmacological manipulation of dopamine receptors in brain , 1987, Neuropharmacology.

[17]  K. Fuxe,et al.  Chronic haloperidol treatment leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum , 1994, Psychopharmacology.

[18]  西田 秀太郎,et al.  リンパ球の機能と Adenosine Receptor , 1982 .

[19]  Keiichi Oda,et al.  Competition between 11C-raclopride and endogenous dopamine in Parkinson's disease , 2010, Nuclear medicine communications.

[20]  E. Parati,et al.  Differential effect of repeated treatment with l-DOPA on dopamine-D1 or -D2 receptors , 1986, Neuropharmacology.

[21]  Suzannah M. Schmidt-Malan,et al.  Continuous and Intermittent Direct Electrical Current 2 , 2015 .

[22]  J. Palacios,et al.  Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease , 1991, Neuroscience.

[23]  Jean Logan,et al.  Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.

[24]  A. Björklund,et al.  l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function , 2002, Neurobiology of Disease.

[25]  M. Savasta,et al.  Denervation supersensitivity of striatal D2 dopamine receptors is restricted to the ventro- and dorsolateral regions of the striatum , 1987, Neuroscience Letters.

[26]  P. Svenningsson,et al.  Adenosine–dopamine interactions , 2003, Neurology.

[27]  P. Molinoff,et al.  Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  Karmen K. Yoder,et al.  Test–retest variability of [11C]raclopride‐binding potential in nontreatment‐seeking alcoholics , 2011, Synapse.

[29]  O. Hornykiewicz,et al.  Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. , 2004, Brain : a journal of neurology.

[30]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[31]  A. Björklund,et al.  L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA , 1998, The European journal of neuroscience.

[32]  Michel Koole,et al.  A Standardized Method for the Construction of Tracer Specific PET and SPECT Rat Brain Templates: Validation and Implementation of a Toolbox , 2015, PloS one.

[33]  Niklas Marklund,et al.  Structured evaluation of rodent behavioral tests used in drug discovery research , 2014, Front. Behav. Neurosci..

[34]  Christer Halldin,et al.  Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: A comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride , 2006, Synapse.

[35]  J. Vanderhaeghen,et al.  Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[36]  K. Jacobson,et al.  Striatal adenosine A(2A) receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [(18)F]-MRS5425. , 2011, Nuclear medicine and biology.

[37]  M. Barrachina,et al.  Increased striatal adenosine A2A receptor levels is an early event in Parkinson’s disease-related pathology and it is potentially regulated by miR-34b , 2014, Neurobiology of Disease.

[38]  P. Fazio,et al.  A2A adenosine receptor overexpression and functionality, as well as TNF‐α levels, correlate with motor symptoms in Parkinson's disease , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  S. Obayashi,et al.  Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats , 2005, Brain Research.

[40]  B. Fredholm,et al.  Pharmacology of adenosine A2A receptors. , 1996, Trends in pharmacological sciences.

[41]  F. Pedata,et al.  Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. , 2002, European journal of pharmacology.

[42]  M. Savasta,et al.  Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission , 1988, Neuroscience Letters.

[43]  A. Lammertsma,et al.  Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil. , 2012, Nuclear medicine and biology.

[44]  Y. Agid,et al.  Continuous and intermittent levodopa differentially affect basal ganglia function , 1989, Annals of neurology.

[45]  B. Neustadt,et al.  Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. , 2007, Bioorganic & medicinal chemistry letters.

[46]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[47]  U. Himmelreich,et al.  Metabolic and Type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease , 2011, Experimental Neurology.

[48]  P. Jenner,et al.  Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment withl-DOPA and carbidopa , 1992, Brain Research.

[49]  S. Duty,et al.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease , 2011, British journal of pharmacology.

[50]  R. D'Hooge,et al.  Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors , 2015, Neurobiology of Aging.

[51]  Steven W. Johnson,et al.  Evaluation of Levodopa Dose and Magnitude of Dopamine Depletion as Risk Factors for Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease , 2007, Journal of Pharmacology and Experimental Therapeutics.

[52]  A. Rivera,et al.  Differential regional and cellular distribution of dopamine D2‐like receptors: An immunocytochemical study of subtype‐specific antibodies in rat and human brain , 1998, The Journal of comparative neurology.

[53]  A. van Waarde,et al.  Synthesis and preclinical evaluation of 2-(2-furanyl)-7-[2-[4-[4-(2-[11C]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amine ([11C]Preladenant) as a PET tracer for the imaging of cerebral adenosine A2A receptors. , 2014, Journal of medicinal chemistry.

[54]  F. Turkheimer,et al.  Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease , 2011, Neurology.

[55]  D. Mash,et al.  Adenosine A2A receptor mRNA expression in Parkinson's disease , 2000, Neuroscience Letters.

[56]  P. Bédard,et al.  Behavioral and biochemical evidence for a different effect of repeated administration of l-DOPA and bromocriptine on denervated versus non-denervated striatal dopamine receptors , 1987, Neuropharmacology.

[57]  Kathleen Vunckx,et al.  Construction and Evaluation of Quantitative Small-Animal PET Probabilistic Atlases for [18F]FDG and [18F]FECT Functional Mapping of the Mouse Brain , 2013, PloS one.

[58]  P. Seeman,et al.  Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[59]  I. Whishaw,et al.  Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6‐OHDA dopamine‐depleted (hemi‐Parkinson analogue) rats , 2001, The European journal of neuroscience.

[60]  Koen Van Laere,et al.  Micro-Positron Emission Tomography Imaging of Rat Brain Metabolism during Expression of Contextual Conditioning , 2012, The Journal of Neuroscience.

[61]  D J Brooks,et al.  Effect of L‐dopa and 6‐hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET , 1995, Synapse.

[62]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[63]  P. Franzone,et al.  An in vivo evaluation , 1989 .

[64]  Paul Greengard,et al.  Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia , 2003, Nature Neuroscience.

[65]  E. Granieri,et al.  A2A adenosine receptors and Parkinson's disease severity , 2014, Acta neurologica Scandinavica.

[66]  I. Kanazawa,et al.  Repeated l-DOPA administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat , 1993, Neuroscience Research.

[67]  E. Bézard,et al.  [L-dopa induced dyskinesia in Parkinson's disease]. , 2015, Bulletin de l'Academie nationale de medecine.

[68]  Koen Van Laere,et al.  Metabolic–dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson’s disease , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[69]  Francesca Fanelli,et al.  Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization , 2003, Journal of Biological Chemistry.

[70]  B. Gulyás,et al.  Effect of amphetamine on dopamine D2 receptor binding in the primate brain with the agonist ligand [11C]MNPA , 2005 .

[71]  K. Fuxe,et al.  Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum , 1992, Brain Research.

[72]  A. Willemsen,et al.  In vivo evaluation of [11C]preladenant positron emission tomography for quantification of adenosine A2A receptors in the rat brain , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.